Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A

Schuster, Tilman; Mühlstein, A; Yaghootfam, Claudia; Maksimenko, Olga; Shipulo, E. V.; Gelperina, Svetlana; Kreuter, Jörg; Gieselmann, Volkmar; Matzner, Ulrich

doi:10.1016/j.jconrel.2017.02.016

Cited by 32 publications

(17 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar stability issues were observed with several types of biodegradable nanoparticles coated with lysosomal hydrolase arylsulfatase A (ASA). 39 Three different binding procedures were compared: adsorption, high-affinity binding via the streptavidin–biotin system, and covalent binding. Interestingly, although adsorption allowed higher amounts of ASA binding, rapid and complete desorption occurred in the presence of phosphate buffer or serum as this binding involves weak chemical forces such as electrostatics, hydrogen bonds, hydrophobic interactions, and van der Waals forces.…”

Section: Results and Discussionmentioning

confidence: 99%

Favorable Biological Responses of Neural Cells and Tissue Interacting with Graphene Oxide Microfibers

et al. 2017

View full text Add to dashboard Cite

Neural tissue engineering approaches show increasing promise for the treatment of neural diseases including spinal cord injury, for which an efficient therapy is still missing. Encouraged by both positive findings on the interaction of carbon nanomaterials such as graphene with neural components and the necessity of more efficient guidance structures for neural repair, we herein study the potential of reduced graphene oxide (rGO) microfibers as substrates for neural growth in the injured central neural tissue. Compact, bendable, and conductive fibers are obtained. When coated with neural adhesive molecules (poly-l-lysine and N-cadherin), these microfibers behave as supportive substrates of highly interconnected cultures composed of neurons and glial cells for up to 21 days. Synaptic contacts close to rGO are identified. Interestingly, the colonization by meningeal fibroblasts is dramatically hindered by N-cadherin coating. Finally, in vivo studies reveal the feasible implantation of these rGO microfibers as a guidance platform in the injured rat spinal cord, without evident signs of subacute local toxicity. These positive findings boost further investigation at longer implantation times to prove the utility of these substrates as components of advanced therapies for enhancing repair in the damaged central neural tissue including the injured spinal cord.

show abstract

Section: Results and Discussionmentioning

confidence: 99%

Favorable Biological Responses of Neural Cells and Tissue Interacting with Graphene Oxide Microfibers

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Moreover, once they are inside the cell the glycoprotein P responsible for returning foreign compounds to the blood is inhibited by this surfactant [13]. Similarly, other surfactants have demonstrated that they have the potential to increase the BBB passage by inhibiting the action of the glycoproteing P such as poloxomers (Pluronics) [14,15], Vitamin E-TPGS (Tocopheryl polyethylene glycol 1000 succinate) [16][17][18] or Brij [13,19]. In addition, due to the inter-individual heterogeneity of the disease, the investigation of its individualized management is nowadays taking on a leading role.…”

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of superparamagnetic nanoparticles and doxorubicin in PLGA nanocarriers: Development, characterization and in vitro antitumor efficacy in glioma cells

Luque-Michel

Sebastián

Larrea

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

With a very poor prognosis and no clear etiology, glioma is the most aggressive cancer in the brain. Thanks to its versatility, nanomedicine is a promising option to overcome the limitations on chemotherapy imposed by the blood brain barrier (BBB). The objective of this paper was to obtain monitored tumor-targeted therapeutic nanoparticles (NPs). To that end, theranostic surfactant-coated polymer poly-Lactic-co-Glycolic Acid (PLGA) nanoplatform encapsulating doxorubicin hydrochloride (DOX) and superparamagnetic iron oxide NPs (SPIONs) were developed. Different non-ionic surfactants known as BBB crossing enhancers (Tween 80, Brij-35, Pluronic F68 or Vitamin E-TPGS) were used to develop 4 types of theranostic nanoplatforms, which were characterized in terms of size and morphology by DLS, TEM and STEM-HAADF analyses. Moreover, the 3-month stability test, the therapeutic efficacy against different glioma cell lines (U87-MG, 9L/LacZ and patient derived-neuronal stem cells) and the Magnetic Resonance Imaging (MRI) relaxivity were studied. Results showed that the synthesised nanoplatforms were stable at 4 ºC after their lyophilization, being that of paramount importance to ensure a long-term stability in a future in vivo application. Furthermore, the theranostic nanoplatforms were efficient in the in vitro treatment of glioma cells, proving to have imaging efficacy as MRI contrast agents. Our results show an efficient loading of drugs and good value of the relaxivity. Therefore, the efficient theranostic hybrid nanoplatform developed here could be used to perform MRI-guided delivery of hydrophobic drugs.

show abstract

“…In general, due to the vulnerability of the brain compartment and the consequent need to maintain its integrity, among all possible strategies, non-invasive ones are to be preferred in developing therapies for the central nervous system (CNS). In the last decade, the nanomedicine-based approach was considered for neurological applications [20], as well as for LSDs treatment [21,22]. Different kinds of polymer can be used for nanoparticles preparation (e.g., poly-lactide-co-glycolide, polyethylene glycol, poly-buthyl/heaxil-cyano-acrylate, albumin, chitosan) as well as different types of inorganic materials (gold, silica, carbon) [23,24].…”

Section: Introductionmentioning

confidence: 99%

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Rigon

Salvalaio

Pederzoli

et al. 2019

IJMS

View full text Add to dashboard Cite

Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the enzyme iduronate 2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans in most organ-systems, including the brain, and resulting in neurological involvement in about two-thirds of the patients. The main treatment is represented by a weekly infusion of the functional enzyme, which cannot cross the blood-brain barrier and reach the central nervous system. In this study, a tailored nanomedicine approach based on brain-targeted polymeric nanoparticles (g7-NPs), loaded with the therapeutic enzyme, was exploited. Fibroblasts from MPSII patients were treated for 7 days with NPs loaded with the IDS enzyme; an induced IDS activity like the one detected in healthy cells was measured, together with a reduction of GAG content to non-pathological levels. An in vivo short-term study in MPSII mice was performed by weekly administration of g7-NPs-IDS. Biochemical, histological, and immunohistochemical evaluations of liver and brain were performed. The 6-weeks treatment produced a significant reduction of GAG deposits in liver and brain tissues, as well as a reduction of some neurological and inflammatory markers (i.e., LAMP2, CD68, GFAP), highlighting a general improvement of the brain pathology. The g7-NPs-IDS approach allowed a brain-targeted enzyme replacement therapy. Based on these positive results, the future aim will be to optimize NP formulation further to gain a higher efficacy of the proposed approach.

show abstract

Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A

Cited by 32 publications

References 63 publications

Favorable Biological Responses of Neural Cells and Tissue Interacting with Graphene Oxide Microfibers

Favorable Biological Responses of Neural Cells and Tissue Interacting with Graphene Oxide Microfibers

Co-encapsulation of superparamagnetic nanoparticles and doxorubicin in PLGA nanocarriers: Development, characterization and in vitro antitumor efficacy in glioma cells

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Contact Info

Product

Resources

About